Amir SohailNew York, USA, (ZM NEWSWIRE) — IgA Nephropathy Clinical Trial Space Intensifies with 25+ Companies in Active Development | DelveInsight
The IgA nephropathy clinical trial analysis report delivers important insights into ongoing research of 30+ pipeline IgA nephropathy drugs, clinical strategies, upcoming therapeutics, and commercial analysis.
DelveInsight’s ‘IgA Nephropathy Pipeline Insight 2026’ report provides comprehensive global coverage of pipeline therapies for IgA nephropathy across various stages of clinical development. The report offers an in-depth analysis of key trends, emerging therapies, and competitive landscape dynamics, highlighting the strategies of major pharmaceutical companies to advance the pipeline and capitalize on future growth opportunities. In addition, it includes critical insights into clinical trial benchmarking, partnering and licensing activities, and regulatory pathways involving the FDA and EMA, enabling stakeholders to make informed decisions and optimize development strategies within the IgA nephropathy domain.
IgA Nephropathy Clinical Trial Analysis Summary
- DelveInsight’s IgA nephropathy pipeline report depicts a robust space with 25+ active players working to develop 30+ pipeline IgA nephropathy drugs.
- Key IgA nephropathy companies, such as Haisco Pharmaceutical Group Co., Ltd, Novartis, Vertex Pharmaceuticals, Biogen, Vera Therapeutics, AstraZeneca (Alexion Pharmaceuticals), F. Hoffmann-La Roche, Ionis Pharmaceuticals, Takeda Pharmaceutical, Arrowhead Pharmaceuticals, NovelMed, Walden Biosciences, Kira Pharmaceuticals, Purespring Therapeutics, Biohaven Therapeutics, Keymed Biosciences Co., Ltd., Nanjing Chia-tai Tianqing Pharmaceutical, Rona Therapeutics, Infinimmune, and others, are evaluating new IgA nephropathy drugs to improve the treatment landscape.
- Promising pipeline IgA Nephropathy therapies, such as HSK39297, Zigakibart (FUB523; formerly known as BION-1301), Povetacicept (ALPN-303), Felzartamab (MOR202), Atacicept, ULTOMIRIS (ravulizumab), Sefaxersen (RG6299; IONIS-FB-LRx), TAK-079 (mezagitamab), ARO-C3, NM8074 (Ruxoprubart), WAL0921, KP104, PS-002, BHV-1400, CM313, NTQ5082, RNK288, IFX 301, and others, are in different phases of IgA nephropathy clinical trials.
- Approximately 12+ IgA nephropathy drugs are in the late stages of development.
- Notable MoAs in IgA nephropathy clinical trials include Complement Factor B inhibitor, BAFF (B cell activating factor) and APRIL antagonist, Antibody-dependent cell cytotoxicity, Gd-IgA1 degrader, RNA interference, CD38 Antagonist, and others.
Request a sample and discover the recent advances in IgA nephropathy drug development @ https://www.delveinsight.com/sample-request/iga-nephropathy-igan-pipeline-insight
What is IgA Nephropathy?
IgA nephropathy (IgAN), also known as Berger’s disease, is a chronic kidney disorder characterized by the abnormal deposition of immunoglobulin A (IgA) antibodies in the glomeruli, the tiny filtering units of the kidneys. This buildup triggers inflammation and progressively impairs the kidneys’ ability to filter waste from the blood. The condition often presents with symptoms such as blood in the urine (hematuria), proteinuria, and, in some cases, high blood pressure or swelling in the hands and feet. While the exact cause is not fully understood, it is believed to involve immune system dysfunction and genetic predisposition. IgA nephropathy can vary widely in severity, ranging from a benign course to gradual progression toward chronic kidney disease or even end-stage renal failure in some patients. Early diagnosis and management are crucial to slowing disease progression and preserving kidney function.
Find out more about IgA nephropathy drug development @ IgA Nephropathy Treatment
A snapshot of the Pipeline IgA Nephropathy Drugs mentioned in the report:
| Drugs | Company | Phase | MoA | RoA |
| HSK39297 | Haisco Pharmaceutical Group Co., Ltd. | III | Complement Factor B inhibitor | Oral |
| Povetacicept | Vertex Pharmaceuticals | III | BAFF (B cell activating factor) and APRIL antagonist | Subcutaneous |
| Zigakibart | Novartis AG | III | Anti-APRIL | Subcutaneous |
| CM313 | Keymed Biosciences Co., Ltd. / Timberley Therapeutics | II | CD38 Antagonist | Subcutaneous |
| NTQ5082 | Nanjing Chia-tai Tianqing Pharmaceutical | II | Complement Factor B inhibitor | Oral |
| BHV-1400 | Biohaven, Ltd. | I | Galactosyl-deficient IgA1 degraders | Subcutaneous |
| RNK288 | Rona Therapeutics | Preclinical | RNA interference | NA |
| IFX 301 | Infinimmune | Preclinical | APRIL modulator | NA |
Learn more about the emerging IgA nephropathy therapies @ IgA Nephropathy Clinical Trials
As per Stuti Mahajan, consulting manager at DelveInsight, the IgA nephropathy treatment is entering a transformative phase with emerging targeted therapies expected to significantly improve disease management and long-term kidney outcomes. Therapies such as Povetacicept and Zigakibart, which target the APRIL/BAFF pathway, along with complement inhibitors like HSK39297 and innovative approaches such as BHV-1400, are designed to address the underlying drivers of IgAN rather than only managing symptoms. These next-generation therapies have the potential to reduce proteinuria more effectively, slow progression to kidney failure, minimize steroid dependence, and support personalized treatment strategies based on patient-specific disease biology. Looking ahead, the IgAN therapeutic landscape is expected to evolve toward precision medicine, combination targeted therapies, and earlier intervention approaches that could deliver more durable disease control and potentially redefine the standard of care in IgAN management.
Recent Developments in IgA Nephropathy Treatment Space
- In May 2026, Vor Bio announced that results from the Phase III TELIGAN trial evaluating telitacicept in IgA nephropathy in China sponsored by its collaborator, RemeGen Co., Ltd., were published in The New England Journal of Medicine (NEJM).
- In March 2026, Vertex Pharmaceuticals Incorporated announced positive data from a pre-specified Week 36 interim analysis of the ongoing Phase III RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation-inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN).
- In November 2025, Vertex Pharmaceuticals reported updated Phase I/II data from the RUBY-3 study at the American Society of Nephrology Kidney Week, continuing to demonstrate the best-in-class potential of povetacicept in adults with IgAN and primary membranous nephropathy.
- In November 2025, Vera Therapeutics reported positive Phase III ORIGIN data for atacicept in IgAN, with results presented at ASN Kidney Week 2025 and published in the New England Journal of Medicine, reinforcing its clinical efficacy and late-stage validation.
- In November 2025, Takeda Pharmaceutical reported new data demonstrating that mezagitamab (TAK-079) produced sustained preservation of kidney function up to 18 months after treatment in patients with primary IgAN.
- In November 2025, Jade Biosciences, Inc. presented two posters for JADE101, its investigational anti-A PRoliferation-Inducing Ligand (APRIL) monoclonal antibody for the treatment of immunoglobulin A nephropathy (IgAN), at the American Society of Nephrology (ASN) Kidney Week 2025.
- In September 2025, Walden Biosciences reported progress on two initiatives supporting WAL0921 development, including advancement of the ongoing Phase II basket study (WAL0921-02) in rare chronic kidney diseases and engagement of a regulatory advisor with targeted patient outreach to support trial execution.
Scope of the IgA Nephropathy Pipeline Report
- Coverage: Global
- IgA Nephropathy Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
- IgA Nephropathy Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- IgA Nephropathy Therapeutics Assessment By Route of Administration: Intra-articular, Intraocular, Intrathecal, Intravenous, Ophthalmic, Oral, Parenteral, Subcutaneous, Topical, Transdermal
- IgA Nephropathy Therapeutics Assessment By Molecule Type: Oligonucleotide, Peptide, Small molecule
- IgA Nephropathy Therapeutics Assessment By Mechanism of Action: Complement Factor B inhibitor, BAFF (B cell activating factor) and APRIL antagonist, Antibody-dependent cell cytotoxicity, Gd-IgA1 degrader, RNA interference, CD38 Antagonist , and others
- Key IgA Nephropathy Companies: Eucure (Beijing) Biopharma Co., Ltd, Novartis, Vertex Pharmaceuticals, Biogen, Vera Therapeutics, AstraZeneca (Alexion Pharmaceuticals), F. Hoffmann-La Roche, Ionis Pharmaceuticals, Takeda Pharmaceutical, Arrowhead Pharmaceuticals, NovelMed, Walden Biosciences, Kira Pharmaceuticals, Purespring Therapeutics, Biohaven Therapeutics, Nanjing Chia-tai Tianqing Pharmaceutical, Keymed Biosciences Co., Ltd., Rona Therapeutics, Infinimmune, and others.
- Key IgA Nephropathy Pipeline Therapies: HSK39297, Zigakibart (FUB523; formerly known as BION-1301), Povetacicept (ALPN-303), Felzartamab (MOR202), Atacicept, ULTOMIRIS (ravulizumab), Sefaxersen (RG6299; IONIS-FB-LRx), TAK-079 (mezagitama), ARO-C3, NM8074 (Ruxoprubart), WAL0921, KP104, PS-002, BHV-1400, CM313, NTQ5082, RNK288, IFX 301, and others.
Dive deep into rich insights for new IgA nephropathy treatments, visit @ IgA Nephropathy Drugs
Table of Contents
| 1. | IgA Nephropathy Pipeline Report Introduction |
| 2. | IgA Nephropathy Pipeline Report Executive Summary |
| 3. | IgA Nephropathy Pipeline: Overview |
| 4. | Analytical Perspective In-depth Commercial Assessment |
| 5. | IgA Nephropathy Clinical Trial Therapeutics |
| 6. | IgA Nephropathy Pipeline: Late-Stage Products (Pre-registration) |
| 7. | IgA Nephropathy Pipeline: Late-Stage Products (Phase III) |
| 8. | IgA Nephropathy Pipeline: Mid-Stage Products (Phase II) |
| 9. | IgA Nephropathy Pipeline: Early-Stage Products (Phase I) |
| 10. | IgA Nephropathy Pipeline Therapeutics Assessment |
| 11. | Inactive Products in the IgA Nephropathy Pipeline |
| 12. | Company-University Collaborations (Licensing/Partnering) Analysis |
| 13. | Key Companies |
| 14. | Key Products in the IgA Nephropathy Pipeline |
| 15. | Unmet Needs |
| 16. | Market Drivers and Barriers |
| 17. | Future Perspectives and Conclusion |
| 18. | Analyst Views |
| 19. | Appendix |
For further information on the IgA nephropathy cure research, reach out @ Medication for IgA Nephropathy Treatment
Related Reports
IgA Nephropathy Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key IgAN companies, including Novartis, Vertex Pharmaceuticals, Biogen, Vera Therapeutics, AstraZeneca (Alexion Pharmaceuticals), F. Hoffmann-La Roche, Ionis Pharmaceuticals, Takeda Pharmaceutical, Arrowhead Pharmaceuticals, NovelMed, Walden Biosciences, Kira Pharmaceuticals, Purespring Therapeutics, Biohaven Therapeutics, and others.
Chronic Kidney Disease Market Insights, Competitive Landscape, and Market Forecast – 2036 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key CKD companies, including ProKidney, Reata Pharmaceuticals, Inc., Novo Nordisk A/S, Boehringer Ingelheim, Eli Lilly and Company, KBP Biosciences, Kibow Pharma, Cincor Pharma, AstraZeneca, Allena Pharmaceuticals, DiaMedica Therapeutics Inc., Lexicon Pharmaceuticals, Sanofi, and others.
Chronic Kidney Disease Clinical Trial Analysis
Chronic Kidney Disease Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key CKD companies, including Novo Nordisk, Prokidney, Kibow Pharma, XORTX Therapeutics, Lisata Therapeutics, Unicycive Therapeutics, Novo Nordisk, Bayer, AstraZeneca, Roche, MC2 Therapeutics, Allena Pharmaceuticals, Boehringer Ingelheim, SCOHIA PHARMA, Regeneron Pharmaceuticals, UnicoCell Biomed, OccuRx, Disc Medicine, Shandong Suncadia Medicine, Sarfez Pharmaceuticals, Rege Nephro, Orgenesis, Healx, Benevolent, and others.
Acute Kidney Injury Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key AKI companies, including Fresenius Medical Care, Baxter International, Medtronic, B. Braun Melsungen AG, Nikkiso Co., Nipro Corporation, Asahi Kasei Medical, AM-Pharma, Atox Bio, Guard Therapeutics, Quark Pharmaceuticals, Angion Biomedica Corp., Pharmazz, Inc., Durect Corporation, Kringle Pharma, bioMérieux, BioPorto Diagnostics, Renalyx, Purespring Therapeutics, Maze Therapeutics, Sentien Biotechnologies, and others.
Acute Kidney Injury Clinical Trial Analysis
Acute Kidney Injury Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key AKI companies, including Fresenius Medical Care, Baxter International, Medtronic, B. Braun Melsungen AG, Nikkiso Co., Nipro Corporation, Asahi Kasei Medical, AM-Pharma, Atox Bio, Guard Therapeutics, Quark Pharmaceuticals, Angion Biomedica Corp., Pharmazz, Inc., Durect Corporation, Kringle Pharma, bioMérieux, BioPorto Diagnostics, Renalyx, Purespring Therapeutics, Maze Therapeutics, Sentien Biotechnologies, and others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Publication Partner: ZM Newswire – Powered By Zeest Media
